ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 60.0% from a year ago
Total equity stood at $323.98M at the end of Q1 FY2026, up 60.0% from a year earlier and up 5.5% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.
Context
- Total equity amounted to 92.8% of total assets at the end of Q1 FY2026, down 1.2 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +60.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 307.22M USD
- Year-over-year change
- +19.2%
- 4-year CAGR
- +65.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 307.22M | +19.2% |
| FY2024 | 2024-12-31 | 257.65M | +70.3% |
| FY2023 | 2023-12-31 | 151.3M | -13.3% |
| FY2022 | 2022-12-31 | 174.46M | +323.2% |
| FY2021 | 2021-12-31 | 41.22M | — |
Total Equity vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's Mar 2026 total equity of $323.98M is the 8th highest of the 11 companies compared; the peer median is $511.3M.
- Its year-over-year change of +60.0% is the 4th highest of 11, against a peer median of +5.7%.
- Total equity amounts to 92.8% of total assets for AVBP, versus a peer median of 76.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $1.84B | -9.3% | -4.6% | 73.9% | |
| Dec 2025 | $1.25B | +62.1% | +25.2% | 71.4% | |
| Mar 2026 | $937.27M | -8.5% | +43.0% | 91.0% | |
| Sep 2026 | $916.74M | +163.5% | -7.6% | 91.8% | |
| Jun 2026 | $607.04M | -23.3% | -11.9% | 56.5% | |
| Mar 2026 | $415.56M | +89.1% | +20.0% | 95.1% | |
| Mar 2026 | $387.58M | +19.8% | +0.2% | 94.1% | |
| Mar 2026 | $323.98M | +60.0% | +20.8% | 92.8% | |
| Jun 2026 | $253.86M | -31.9% | -22.4% | 34.1% | |
| Mar 2026 | $128.42M | +32.2% | +82.0% | 66.6% | |
| Mar 2026 | $104.3M | -26.3% | -1.0% | 78.5% | |
| Peer median (excluding AVBP) | $511.3M | +5.7% | -0.4% | 76.2% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37.28M | 163.37M | 150.39M | 74.29M | 45.54M |
| Short-term Investments | 0 | 0 | 0 | 144.57M | 267.28M |
| Net Receivables | 0 | 0 | 0 | 500K | 60K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.64M | 18.92M | 9.21M | 7.21M | 20.02M |
| Total Current Assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.9M |
| Property, Plant & Equipment (Net) | 0 | 139K | 291K | 154K | 13K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 47.68M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87K | 72K | 2.84M | 126K | 259K |
| Total Non-current Assets | 87K | 211K | 3.13M | 47.96M | 272K |
| Total Assets | 43.04M | 182.83M | 163.1M | 274.94M | 333.17M |
| Account Payables | 293K | 3.09M | 4.53M | 3.78M | 5.93M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 4.16M | 6.55M |
| Total Current Liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 11K | 177K | 14K | 0 |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.29M | 25.95M |
| Common Stock | 0 | 0 | 0 | 3K | 4K |
| Retained Earnings | (51.61M) | (88.51M) | (157.85M) | (238.33M) | (404.64M) |
| Accumulated OCI | (2K) | 0 | 0 | (211K) | 14K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.22M | 174.46M | 151.3M | 257.65M | 307.22M |
| Total Debt | 0 | 139K | 317K | 176K | 14K |
| Net Debt | (37.28M) | (163.23M) | (150.07M) | (74.12M) | (45.53M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.